John L. Higgins - Feb 15, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
By: Charles S. Berkman For: John L. Higgins
Stock symbol
LGND
Transactions as of
Feb 15, 2022
Transactions value $
-$732,557
Form type
4
Date filed
2/16/2022, 07:23 PM
Previous filing
Jan 28, 2022
Next filing
May 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability -$241K -1.95K -0.56% $123.68 345K Feb 15, 2022 Direct F1
transaction LGND Common Stock Tax liability -$255K -2.06K -0.6% $123.68 343K Feb 15, 2022 Direct F2
transaction LGND Common Stock Tax liability -$237K -1.92K -0.56% $123.68 341K Feb 15, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.
F2 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.
F3 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021.